If the 19th century was the century of chemistry and the 20th the century of physics, we believe the 21st will be the century of biology.
As we unravel secrets about DNA and deploy that knowledge to re-engineer biological systems, we believe revolutionary advances will continually transform industries from healthcare, agriculture and manufacturing to energy production, consumer services and data storage creating a historic investment opportunity. To help investors capitalize, we leveraged the insights of futurist Jamie Metzl, member of the World Health Organization’s expert committee on human genome editing, to launch a revolutionary new ETF, the WisdomTree BioRevolution Fund (WDNA).
The biology revolution is rapidly improving our ability to understand, read, write, and hack DNA, the genetic code of all life. Learn how the WisdomTree BioRevolution Fund (WDNA) can help capitalize on this megatrend.
In this Office Hours replay, Global Head of Research Chris Gannatti is joined by Jamie Metzl, Founder and Chair of OneShared.World for an in-depth discussion regarding the extended period of very challenging returns within the broader equity market, and how we believe the tide could turn in 2024 across the Biotechnology landscape.
Jamie Metzl (2022)
In an insightful panel, Dubai Future Forum welcomed Dr. Jamie Metzl, Founder and Chair, OneShared.World, where he discussed the three essential steps that lead to imagining the future of our species. WisdomTree partnered with Jamie to shape the WisdomTree BioRevolution Fund (WDNA).
Jamie Metzl (TEDxPaloAlto)
DNA sequencing is at the core of the BioRevolution. In this thought-provoking TED Talk, renowned futurist and thought leader on the BioRevolution, Jamie Metzl, breaks down the how’s, why’s and what-if’s of the genetic revolution that is transforming this century. WisdomTree partnered with Jamie to shape the new WisdomTree BioRevolution Fund (WDNA).
Statements concerning trends in the fields, industries and sectors discussed are based on current conditions, which will fluctuate. References to specific securities and their issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. This material represents an assessment of trends discussed at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This material should not be relied upon as research or investment advice regarding any security in particular. The user of this information assumes the entire risk of any use made of the information provided herein.
AI is reshaping industries far beyond tech, and broad ETFs may miss the mark. Christopher Gannatti explains how WisdomTree’s six specialized Funds segment AI exposure across cybersecurity, biotech, cloud and more, helping investors to truly align with the component of the AI economy for which they are seeking exposure.
In developed international equities, with a tougher period for equities in 2025 value and high dividends have delivered relative outperformance. Christopher Gannatti unpacks why the early 2025 outperformance of the WisdomTree International High Dividend Fund signals a shift in investor sentiment and how sector tilts and yield dynamics set it apart from quality-focused strategies like the WisdomTree International Quality Dividend Growth Fund.
After years of underwhelming performance, biotech may finally be ready for a breakthrough in 2025. Chris Gannatti highlights how advancements in gene editing, AI-driven drug discovery and policy support are laying the foundation for a sector-wide resurgence.
For more daily insights from our thought leaders, visit our blog.
